A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Inclusion Criteria: * Advanced cancer of the lymph nodes of follicular type at study inclusion * The patient has relapsed or has refractory disease, after previous treatment with rituximab * Treating physician has decided to treat the patient with a 90Y-Zevalin regimen * The patient is \>= 18 years of age * Patient has given informed consent Exclusion Criteria: * Patient is unwilling or unable to give informed consent * Patient is participating in another clinical trial